呼吸道疾病疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、感染類型、分銷管道、地區和競爭格局分類，2021-2031年

全球呼吸道疾病疫苗市場預計將從 2025 年的 956.9 億美元成長到 2031 年的 1,024.9 億美元，複合年成長率為 1.15%。

這些疫苗是一種旨在誘導人體對感染肺部和呼吸道的病原體（例如流感病毒、呼吸道融合細胞病毒和肺炎球菌）產生主動獲得性免疫的生物製藥。該領域的成長主要得益於全球老年人口的不斷增加，他們容易罹患嚴重的呼吸系統疾病，以及全球感染疾病負擔的日益加重。此外，各國政府在醫療保健免疫舉措的大量投入以及支持快速核准的法規結構也積極推動了市場擴張。正如國際藥品製造商協會聯合會（IFPMA）在2024年指出的那樣，目前在開發平臺疫苗超過285種，這凸顯了該行業致力於應對感染疾病風險的堅定決心。

儘管存在這些成長要素，但由於低溫運輸配送相關的複雜物流要求，市場仍面臨許多障礙。在發展中地區，維持整個供應鏈的溫度控制是一項挑戰，這限制了市場覆蓋範圍，並增加了產品劣化的風險。這些物流限制阻礙了新興市場的進入，並妨礙了製造商充分利用全球對先進呼吸系統免疫解決方案的需求。

市場促進因素

創新呼吸道合胞病毒（RSV）和肺炎球菌疫苗的快速商業化顯著擴大了市場，尤其是在老年人群體中。首個老年人RSV疫苗的核准填補了醫療保健領域的關鍵空白，並促成了產品的快速普及。這種使用量的增加為生產商帶來了盈利的收入，並凸顯了解決老齡化呼吸道疾病易感性問題的商業性潛力。例如，葛蘭素史克（GSK）在其「2023年全年及第四季」報告中指出，其Alexby疫苗上市首年銷售額達到12億英鎊，顯示這些新型預防措施具有巨大的市場價值。這個新類別的成功建立正在增強主要行業參與者的整體財務穩定性。賽諾菲在2024年2月發布的新聞稿也印證了這一點，新聞稿稱，其呼吸道和免疫產品組合的年度疫苗總銷售額已達75億歐元。

同時，mRNA和重組蛋白技術的快速發展正在徹底改變疫苗的研發和生產。各公司正優先利用這些高度靈活的平台來設計多價候選疫苗，以期透過單劑接種即可抵禦多種威脅，例如流感和新冠肺炎。這種向先進技術模式的策略轉變需要對臨床試驗進行大量投資，以驗證疫苗的有效性並改善給藥方法。根据Moderna公司于2024年2月发布的“2023财年第四季度及全年财务业绩报告”，其研发支出增至48亿美元。這一成長主要得益於該公司呼吸系統疾病疫苗和聯合疫苗研發計劃的後期臨床試驗。此類投資凸顯了疫苗產業利用靈活平台來減輕季節性病毒影響並加強應對疫情準備的決心。

市場挑戰

低溫運輸配送所需的複雜物流對全球呼吸道疾病疫苗市場的擴張構成重大障礙。呼吸道疫苗，尤其是流感和肺炎球菌疾病的疫苗，屬於生物活性極低的疫苗，需要從生產到接種全程冷藏。許多新興經濟體缺乏維持這種嚴格溫度控制的基礎設施，增加了產品劣化和效力降低的風險。這種物流方面的不足給生產商帶來了高昂的營運成本和技術挑戰，阻礙了供應鏈向需求旺盛但基礎設施低度開發地區的擴張。因此，無法保證產品品質成為直接的市場准入壁壘，有效縮小了先進免疫療法的潛在市場。

開發中國家市場滲透率持續存在的差距凸顯了這項挑戰的嚴峻性。根據全球疫苗免疫聯盟（Gavi）2024年的報告，低收入國家仍有約1,020萬兒童未接種疫苗，顯示維持有效的供應鏈，並向偏遠社區提供疫苗，仍然困難重重。如此巨大的疫苗覆蓋不足清楚地表明，物流限制和低溫運輸中斷如何直接阻礙了疫苗行業滿足全球需求的能力，阻礙了收入成長和市場多元化。

市場趨勢

孕期免疫接種的策略轉變正在改變全球呼吸道疾病疫苗市場，填補了嬰幼兒群體中直接接種疫苗困難所導致的關鍵免疫缺口。製藥公司正日益關注孕期接種的疫苗，這些疫苗能夠透過胎盤傳遞保護性抗體，尤其是針對呼吸道融合細胞病毒（RSV）的疫苗。這種方法能夠有效降低新生兒嚴重下呼吸道感染疾病的發生率，而此類感染歷來導致較高的住院率。儘管存在季節性波動，但已通過核准的孕期疫苗配方仍持續被市場接受，這證明了該策略的商業性成功。根據輝瑞公司2025年11月發布的「2025年第三季業績強勁」新聞稿，該公司旗下的Ablisvo疫苗第三季全球銷售額達2.79億美元，凸顯了市場對擴大免疫覆蓋範圍（包括懷孕保護）的需求。

同時，通用流感疫苗候選藥物的研發正在穩步推進，這是克服季節性病毒株不匹配挑戰的關鍵一步。科學家不再局限於設計針對特定病毒株的疫苗，而是將目標轉向保守的病毒表位，例如血凝素莖，旨在實現對多種流感亞型的廣泛且持久的免疫力。這一趨勢的特點是，旨在提供多季保護並降低流感大流行威脅的新一代候選疫苗的臨床試驗數量正在增加。根據明尼蘇達大學感染疾病研究與政策中心（CIDRAP）發布的《通用流感疫苗技術趨勢更新（2025年11月）》，美國國家過敏症和感染疾病研究所（NIAID）正在支持啟動兩種具有廣譜功效的新型流感疫苗候選藥物的二期臨床試驗，這表明開發平臺已相當成熟。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球呼吸系統疾病疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 種類別（ウイルスワクチン、細菌ワクチン、複合ワクチン）
  • 按類型分類的感染疾病（COVID-19、流感、呼吸道融合細胞病毒(RSV)、肺炎、其他）
  • 分銷通路（醫院/零售藥局、政府供應商、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北米の呼吸器疾患ワクチン市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲呼吸系統疾病疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章 アジア太平洋地域の呼吸器疾患ワクチン市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲呼吸系統疾病疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲呼吸系統疾病疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球呼吸系統疾病疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GSK plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• SINOVAC Biotech Ltd.
• Bavarian Nordic A/S
• Merck & Co., Inc.
• AstraZeneca Plc.
• Moderna Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Respiratory Disease Vaccine Market is projected to expand from a valuation of USD 95.69 Billion in 2025 to USD 102.49 Billion by 2031, reflecting a compound annual growth rate of 1.15%. These vaccines are immunobiological formulations intended to induce active acquired immunity against pathogens that infect the lungs and airways, such as influenza, respiratory syncytial virus, and pneumococcal bacteria. Growth in this sector is largely propelled by an increasing global elderly population prone to severe respiratory issues, alongside the growing burden of infectious diseases worldwide. Additionally, substantial government spending on healthcare immunization initiatives and supportive regulatory frameworks for faster approvals actively encourage market expansion. As noted by the International Federation of Pharmaceutical Manufacturers and Associations in 2024, the development pipeline contained over 285 vaccine candidates, highlighting significant industrial commitment to combating infectious health risks.

Despite these positive growth factors, the market encounters a major hurdle due to the intricate logistics necessitated by cold chain distribution. Ensuring consistent temperature regulation across the supply chain poses a challenge in developing areas, which restricts market reach and raises the likelihood of product spoilage. This logistical limitation establishes a barrier to entry in emerging markets and hampers manufacturers' capacity to fully leverage the global demand for sophisticated respiratory immunization solutions.

Market Driver

The rapid commercialization of innovative RSV and pneumococcal vaccines has substantially broadened the market, especially within the elderly demographic. The recent authorization of first-in-class RSV vaccines for older adults has addressed a significant void in preventative healthcare, leading to prompt and extensive product adoption. This increase in utilization has generated a profitable revenue channel for manufacturers, confirming the commercial potential of addressing age-related respiratory susceptibilities. For example, GSK reported in its "Full-year and fourth quarter 2023" document that its Arexvy vaccine achieved sales of £1.2 billion in its debut year, illustrating the immense market value of these new prophylactic measures. This successful establishment of a new category bolsters the overall financial stability of leading industry participants, as evidenced by Sanofi's February 2024 press release stating that total vaccine sales hit €7.5 billion for the year, propelled by their advancing respiratory and immunization portfolio.

At the same time, the swift uptake of mRNA and recombinant protein technologies is revolutionizing the terrain of vaccine creation and manufacturing. Firms are prioritizing these adaptable platforms to design multivalent candidates that can combat simultaneous threats, such as influenza and COVID-19, in a single dose. This strategic shift towards sophisticated modalities necessitates heavy investment in clinical trials to confirm effectiveness and refine delivery methods. According to Moderna's "Fourth Quarter and Fiscal Year 2023 Financial Results" from February 2024, research and development spending rose to $4.8 billion, an increase primarily driven by late-stage trials for their respiratory and combination vaccine initiatives. Such financial dedication highlights the industry's determination to utilize flexible platforms to alleviate seasonal viral impacts and improve pandemic preparedness.

Market Challenge

The intricate logistics demanded by cold chain distribution present a significant barrier to the expansion of the Global Respiratory Disease Vaccine Market. Respiratory vaccines, especially those designed for influenza and pneumococcal bacteria, are biologically delicate items that require continuous refrigeration from production through to administration. In numerous emerging economies, the infrastructure needed to maintain this rigorous temperature control is often insufficient, resulting in an increased danger of product deterioration and loss of potency. This logistical weakness compels manufacturers to face higher operational expenses and technical challenges, which deters the extension of supply chains into regions with high demand but poor infrastructure. Consequently, the inability to assure product quality serves as a direct obstacle to entry, effectively diminishing the potential market for advanced immunization therapies.

The gravity of this challenge is highlighted by the enduring disparity in market penetration within developing countries. As reported by Gavi, the Vaccine Alliance in 2024, there were roughly 10.2 million zero-dose children in lower-income nations, a statistic that underscores the ongoing difficulty in sustaining functional supply chains required to deliver effective vaccines to isolated populations. This large volume of unreached people illustrates how logistical constraints and cold chain breakdowns directly impede the industry's capacity to meet global demand, thereby hindering revenue expansion and market diversification.

Market Trends

The strategic movement towards maternal immunization is transforming the Global Respiratory Disease Vaccine Market by filling the critical immunity void in infants too young for direct vaccination. Pharmaceutical companies are increasingly concentrating on vaccines given during pregnancy to enable the transfer of protective antibodies across the placenta, specifically targeting respiratory syncytial virus (RSV). This method effectively lowers the incidence of severe lower respiratory tract infections in newborns, a group historically prone to high rates of hospitalization. The commercial success of this strategy is demonstrated by the continued uptake of approved maternal formulations despite seasonal variations. As per Pfizer's "Pfizer Reports Solid Third-Quarter 2025 Results" press release from November 2025, the company's Abrysvo vaccine brought in $279 million in global revenue during the third quarter, confirming the market desire to broaden immunization scope to include maternal protection.

Simultaneously, the development of universal influenza vaccine candidates marks a crucial step forward intended to surmount the issues of seasonal strain mismatches. Scientists are advancing beyond strain-specific designs to target conserved viral epitopes, like the hemagglutinin stalk, aiming to deliver broad-spectrum and long-lasting immunity against various influenza subtypes. This trend is defined by an increase in the clinical testing of next-generation candidates engineered to provide multi-season defense and reduce pandemic threats. According to the "November 2025 updates to the Universal Influenza Vaccine Technology Landscape" report by the University of Minnesota's Center for Infectious Disease Research and Policy, the National Institute of Allergy and Infectious Diseases (NIAID) backed the launch of two new Phase 2 clinical trials for broadly protective influenza vaccine candidates, indicating a substantial maturation of the development pipeline.

Key Market Players

• GSK plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• SINOVAC Biotech Ltd.
• Bavarian Nordic A/S
• Merck & Co., Inc.
• AstraZeneca Plc.
• Moderna Inc

Report Scope

In this report, the Global Respiratory Disease Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Disease Vaccine Market, By Type

• Viral Vaccine
• Bacterial Vaccine
• Combination Vaccine

Respiratory Disease Vaccine Market, By Infection

• COVID-19
• Influenza
• Respiratory Syncytial Virus (RSV)
• Pneumonia
• Others

Respiratory Disease Vaccine Market, By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Respiratory Disease Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Vaccine Market.

Available Customizations:

Global Respiratory Disease Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Disease Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine)
  • 5.2.2. By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Others)
  • 5.2.3. By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Respiratory Disease Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Infection
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Disease Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Infection
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Respiratory Disease Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Infection
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Respiratory Disease Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Infection
      • 6.3.3.2.3. By Distribution Channel

7. Europe Respiratory Disease Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Infection
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Disease Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Infection
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Respiratory Disease Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Infection
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Respiratory Disease Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Infection
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Respiratory Disease Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Infection
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Respiratory Disease Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Infection
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Respiratory Disease Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Infection
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Respiratory Disease Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Infection
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Respiratory Disease Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Infection
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Respiratory Disease Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Infection
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Respiratory Disease Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Infection
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Respiratory Disease Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Infection
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Respiratory Disease Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Infection
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Respiratory Disease Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Infection
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Respiratory Disease Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Infection
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Respiratory Disease Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Infection
      • 9.3.3.2.3. By Distribution Channel

10. South America Respiratory Disease Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Infection
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Respiratory Disease Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Infection
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Respiratory Disease Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Infection
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Respiratory Disease Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Infection
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Respiratory Disease Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GSK plc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Services, Inc.
• 15.3. Pfizer Inc.
• 15.4. Sanofi SA
• 15.5. Serum Institute of India Pvt. Ltd.
• 15.6. SINOVAC Biotech Ltd.
• 15.7. Bavarian Nordic A/S
• 15.8. Merck & Co., Inc.
• 15.9. AstraZeneca Plc.
• 15.10. Moderna Inc

16. Strategic Recommendations

17. About Us & Disclaimer